 Connection
Margaret Wierman to Dehydroepiandrosterone
This is a "connection" page, showing publications Margaret Wierman has written about Dehydroepiandrosterone.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.054 |
|
|
|
-
Wierman ME, Kiseljak-Vassiliades K. Should Dehydroepiandrosterone Be Administered to Women? J Clin Endocrinol Metab. 2022 05 17; 107(6):1679-1685.
Score: 0.781
-
Wierman ME. Why Focus on Androgens in Women? Endocrinol Metab Clin North Am. 2021 03; 50(1):xv-xvi.
Score: 0.177
-
Hirshman E, Merritt P, Wang CC, Wierman M, Budescu DV, Kohrt W, Templin JL, Bhasin S. Evidence that androgenic and estrogenic metabolites contribute to the effects of dehydroepiandrosterone on cognition in postmenopausal women. Horm Behav. 2004 Feb; 45(2):144-55.
Score: 0.055
-
Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med. 2010 Jan; 7(1 Pt 2):314-26.
Score: 0.021
-
Wierman ME, Beardsworth DE, Crawford JD, Crigler JF, Mansfield MJ, Bode HH, Boepple PA, Kushner DC, Crowley WF. Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche. J Clin Invest. 1986 Jan; 77(1):121-6.
Score: 0.016
-
Boepple PA, Mansfield MJ, Wierman ME, Rudlin CR, Bode HH, Crigler JF, Crawford JD, Crowley WF. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty. Endocr Rev. 1986 Feb; 7(1):24-33.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|